All Episodes

Journal Club: Efficacy and Safety of Guselkumab in Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results

FAQ: How does the guselkumab data align with the STRIDE II guidelines?

Medication Review: What are guselkumab's other FDA indications and how might that affect patient care?

KOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?

FAQ: What should patients know about living with cirrhosis?

FAQ: What are predictive risk factors for disease severity in CD and UC?

FAQ: What lifestyle changes are essential for managing cirrhosis effectively?

Journal Club: Guselkumab Efficacy & Safety in Moderate to Severe CD-GALAXI 2 & 3 Results

FAQ: How Can You Support a Shared Decision-Making Process With the Patient?

Medication Review: What is the efficacy of guselkumab in ulcerative colitis and Crohn's disease?

FAQ: How can physicians better care for patients with cirrhosis?

Medication Review: What is the safety profile of guselkumab in ulcerative colitis and Crohn's disease?

Journal Club: Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

GHAPPcast Part 3: Provider & Patient Support

FAQ: Is there a correlation of myeloid cells expressing CD64 and endoscopy disease severity?

GHAPPcast Part 2: Diagnosis and Management

FAQ: Why is binding CD64+ important when discussing IL23 directed therapy?

GHAPPcast Part 1: Understanding Chronic Liver Disease and Cirrhosis

Medication Review: How is guselkumab dosed in IBD?

GHAPPcast: CD64+ Binding: Description, Relevance, and Potential Clinical Implications

FAQ: Provide immunologic rationale for IL23 directed therapy in IBD(+ general overview of Guselkumab MOA)

Journal Club: Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

Medication Review: What is non-responder imputation and how is it utilized in clinical trials?

FAQ: What is the role of IL23/IL17 axis in IBD

FAQ: Describe the IL23/IL17 axis

GHAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of IBD

Medication Review: Describe the mechanism of action of guselkumab

FAQ: Define, compare, and contrast humoral and cell-mediated immunity.

GHAPPcast: CSID in Adults: Clinical Pearls & the Patient Journey

GHAPP PBC Podcast Series Part 2: New Therapeutics In The PBC Space

GHAPP PBC Podcast Series Part 1: Prevalence, Awareness and Identification of PBC

GHAPP PBC Podcast Series Part 3: The Key Highlights of PBC at the GHAPP Conference 2024

KOL Conversation: A New Treatment Option

KOL Conversation: New & Emerging Treatment Considerations for PBC & PBC Pruritus

Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

FAQ: What is MASH?

Medication Review Video Module: What is Resmetirom and how does it work to treat MASH?

FAQ: What are the consequences of NASH going untreated?

FAQ: How is MASH severity staged? What would an ideal MASH NIT algorithm look like?

Medication Review: What is the clinical profile of Resmetirom, including dosing schedules?

GHAPPcast: Recognizing the Severity of MASH

FAQ: Best practices to accelerate the time to finding the right therapy for your patients with IBS-C?

GHAPPcast: Navigating IBS: Pathophysiology, Neuromodulators, and Patient-Centered Care

FAQ: What does it mean for a biosimilar to be interchangeable and why is that important?

FAQ: What resources do you use to understand the latest approaches to managing IBS-C patients?

FAQ: What are some best practices in determining clinically meaningful “response” to therapy for IBS-C patients?

GHAPPcast: Biosimilars and the Patient Perspective

GHAPPcast: Mastering IBS-C: Diagnostic Strategies, Differentiation, and Management.

FAQ: What is the Difference Between Biosimilars and Generics?

FAQ: What Role Does a New Mechanism of Action Play in Your Prescribing Decisions of IBS-C Therapy?

GHAPPcast: Biosimilars Unveiled: Empowering APPs for Better Patient Conversations

CLDF/GHAPP Roundtable Podcast Series: MASH with Nadege Gunn, MD, Elizabeth Goacher, PA, and Ann Moore, FNP

Discussing Biosimilars With Patients

The Nocebo Effect

The Practical Use of Biosimilars in Gastroenterology APP Practice

The Practical Use of Biosimilars in Rheumatology APP Practice

The Benefits of Biosimilars

Managed Care and Biosimilars

Interchangeability & Switching of Biosimilars

Biosimilar Extrapolation

The Difference Between Biosimilars & Generic Drugs

The Regulatory Pathway to Biosimilar Approval

Development of Biosimilars

Biosimilars Series: What Are Biosimilars?